Expression of major histocompatibility complex class II antigen in neoplastic cells of canine cutaneous histiocytoma.
Forty five cases of canine cutaneous histiocytoma (CCH) were examined by immunohistology for expression and distribution of major histocompatibility complex (MHC) class II antigen in neoplastic cells. In addition, expression of lysozyme and calprotectin (leucocyte protein L1) in neoplastic cells was investigated. Furthermore, B and T lymphocytes were demonstrated by antibodies against the CD3 antigen, IgG, and IgM. Neoplastic cells showed two staining patterns for MHC class II antigen: focal juxtanuclear cytoplasmic staining and/or rim-like staining along the cell periphery. In 24 cases, a predominant or exclusive focal juxtanuclear cytoplasmic MHC class II antigen reaction in neoplastic cells, and the presence of few diffusely distributed infiltrating CD3 antigen-positive T lymphocytes were observed. Tumors with numerous neoplastic cells exhibiting staining for MHC class II antigen along the cell periphery (n = 21) showed increased inflammatory alterations, represented by disseminated and nodular infiltrations of mainly CD3 antigen-positive T cells. B cells, plasma cells, exudate macrophages, and neutrophils were rarely seen disseminated between neoplastic cells whereas their number increased within focal inflammatory infiltrates. The focal cytoplasmic reaction for MHC class II antigen in neoplastic cells might represent newly synthesized MHC class II molecules stored in vesicles, whereas staining of the cell periphery might occur due to accumulation of MHC class II molecules along the plasma membrane. The increasing expression of MHC class II molecules on the cell surface might be the decisive factor for onset and progression of tumor regression. However, the exact mechanism of priming and activation of T cells by neoplastic cells and the nature of the presented antigen are not yet known.
Kipar
A
A
Institut für Veterinär-Pathologie, Universität Leipzig, Germany. kipar@rz.uni-leipzig.de
Baumgärtner
W
W
Kremmer
E
E
Frese
K
K
Weiss
E
E
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D004285:Dogs; D005260:Female; D018219:Histiocytoma, Benign Fibrous / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D000949:Histocompatibility Antigens Class II / Q000378:metabolism*; D007124:Immunoenzyme Techniques / Q000662:veterinary; D039841:Leukocyte L1 Antigen Complex; D008285:Major Histocompatibility Complex; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D009113:Muramidase / Q000378:metabolism; D019006:Neural Cell Adhesion Molecules / Q000378:metabolism; D012878:Skin Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000662:veterinary*; D013601:T-Lymphocytes / Q000276:immunology
D017252:CD3 Complex; D000949:Histocompatibility Antigens Class II; D039841:Leukocyte L1 Antigen Complex; D008562:Membrane Glycoproteins; D019006:Neural Cell Adhesion Molecules; D009113:Muramidase